Alpha 2.0
Login Register
» Articles » PMID: 11865016

Changes in Age Related Seroprevalence of Antibody to Varicella Zoster Virus: Impact on Vaccine Strategy

Overview
Journal J Clin Pathol
Specialty Pathology
Date 2002 Feb 28
PMID 11865016
Citations 16
Authors
G Kudesia
S Partridge
C P Farrington
N Soltanpoor
Affiliations
Soon will be listed here.
Abstract

Aim: To study changes in the seroprevalence of varicella zoster virus (VZV) antibody over the past 25 years with a view to determining the target age group for any future vaccination strategy.

Methods: Stored sera collected from different age groups over a period of 25 years were tested by a commercial VZV IgG enzyme immunoassay at a four year time interval. Data were analysed by logistic regression to investigate the evidence for changes in incidence and hence seroprevalence over that period.

Results: There was a significant rise in VZV antibody prevalence in the 1-4 year age group during the study period.

Conclusions: A universal childhood VZV vaccination strategy will need to take account of the increase in incidence of VZV infection in children under the age of 4 years; hence, the suggested target age would be between 12 and 18 months---soon after the disappearance of maternal antibody.

Citing Articles

Modeling the Impact of Exogenous Boosting and Universal Varicella Vaccination on the Clinical and Economic Burden of Varicella and Herpes Zoster in a Dynamic Population for England and Wales.

Sharomi O, Xausa I, Nachbar R, Pillsbury M, Matthews I, Petigara T Vaccines (Basel). 2022; 10(9).

PMID: 36146493 PMC: 9501498. DOI: 10.3390/vaccines10091416.

Herpesviridae prevalence in aqueous humor using PCR.

Keorochana N, Intaraprasong W, Choontanom R Clin Ophthalmol. 2018; 12:1707-1711.

PMID: 30233134 PMC: 6135072. DOI: 10.2147/OPTH.S174694.

A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data.

Bollaerts K, Riera-Montes M, Heininger U, Hens N, Souverain A, Verstraeten T Epidemiol Infect. 2017; 145(13):2666-2677.

PMID: 28826422 PMC: 5647669. DOI: 10.1017/S0950268817001546.

Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.

Riera-Montes M, Bollaerts K, Heininger U, Hens N, Gabutti G, Gil A BMC Infect Dis. 2017; 17(1):353.

PMID: 28521810 PMC: 5437534. DOI: 10.1186/s12879-017-2445-2.

Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.

Dubey A, Faridi M, Mitra M, Kaur I, Dabas A, Choudhury J Hum Vaccin Immunother. 2017; 13(9):2032-2037.

PMID: 28509605 PMC: 5612528. DOI: 10.1080/21645515.2017.1318236.

References
1.
Joseph C, Noah N . Epidemiology of chickenpox in England and Wales, 1967-85. Br Med J (Clin Res Ed). 1988; 296(6623):673-6. PMC: 2545295. DOI: 10.1136/bmj.296.6623.673. View
2.
Sloan D, Burlison A . Shift in age in chickenpox. Lancet. 1992; 340(8825):974. DOI: 10.1016/0140-6736(92)92860-i. View
3.
Miller E, Vardien J, Farrington P . Shift in age in chickenpox. Lancet. 1993; 341(8840):308-9. DOI: 10.1016/0140-6736(93)92663-e. View
4.
Vazquez M, LaRussa P, Gershon A, Steinberg S, Freudigman K, Shapiro E . The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001; 344(13):955-60. DOI: 10.1056/NEJM200103293441302. View
5.
Coyle P, McCaughey C, Wyatt D, ONeill H . Varicella vaccine in pregnancy. Testing should be offered to women without a history of chickenpox. BMJ. 1997; 314(7075):226. PMC: 2125690. View